A replication-competent adenovirus-human immunodeficiency virus (Ad-HIV) tat and Ad-HIV env priming/Tat and envelope protein boosting regimen elicits enhanced protective efficacy against simian/human immunodeficiency virus SHIV89.6P challenge in rhe
about
Mucosal HIV transmission and vaccination strategies through oral compared with vaginal and rectal routesNonhuman primate models for HIV/AIDS vaccine developmentSurvivors Remorse: antibody-mediated protection against HIV-1.Mucosal immunity and protection against HIV/SIV infection: strategies and challenges for vaccine design.Obstacles to the successful development of an efficacious T cell-inducing HIV-1 vaccine.HIV-1 Tat-based vaccines: an overview and perspectives in the field of HIV/AIDS vaccine development.The presence of anti-Tat antibodies in HIV-infected individuals is associated with containment of CD4+ T-cell decay and viral load, and with delay of disease progression: results of a 3-year cohort studyConstruction and immunogenicity of replication-competent adenovirus 5 host range mutant recombinants expressing HIV-1 gp160 of SF162 and TV1 strains.Role of humoral immunity in host defense against HIV.Humoral immunity induced by mucosal and/or systemic SIV-specific vaccine platforms suggests novel combinatorial approaches for enhancing responses.Multiple vaccine-elicited nonneutralizing antienvelope antibody activities contribute to protective efficacy by reducing both acute and chronic viremia following simian/human immunodeficiency virus SHIV89.6P challenge in rhesus macaques.IIIa deleted adenovirus as a single-cycle genome replicating vector.Protection in macaques immunized with HIV-1 candidate vaccines can be predicted using the kinetics of their neutralizing antibodies.Challenges in HIV Vaccine Research for Treatment and Prevention.HIV-1 tat promotes integrin-mediated HIV transmission to dendritic cells by binding Env spikes and competes neutralization by anti-HIV antibodiesGenomic analysis reveals pre- and postchallenge differences in a rhesus macaque AIDS vaccine trial: insights into mechanisms of vaccine efficacyComparative analysis of SIV-specific cellular immune responses induced by different vaccine platforms in rhesus macaquesEffects of the deletion of early region 4 (E4) open reading frame 1 (orf1), orf1-2, orf1-3 and orf1-4 on virus-host cell interaction, transgene expression, and immunogenicity of replicating adenovirus HIV vaccine vectors.HIV-1 CD4-induced (CD4i) gp120 epitope vaccines promote B and T-cell responses that contribute to reduced viral loads in rhesus macaquesStrong viremia control in vaccinated macaques does not prevent gradual Th17 cell loss from central memory.Prime-boost vaccination with heterologous live vectors encoding SIV gag and multimeric HIV-1 gp160 protein: efficacy against repeated mucosal R5 clade C SHIV challenges.Vaccine induced antibodies to the first variable loop of human immunodeficiency virus type 1 gp120, mediate antibody-dependent virus inhibition in macaques.Replicating adenovirus-simian immunodeficiency virus (SIV) recombinant priming and envelope protein boosting elicits localized, mucosal IgA immunity in rhesus macaques correlated with delayed acquisition following a repeated low-dose rectal SIV(mac2HIV Envelope Trimer Specific Immune Response Is Influenced by Different Adjuvant Formulations and Heterologous Prime-Boost.Beyond Oncolytics: E1B55K-Deleted Adenovirus as a Vaccine Delivery Vector.Protection against simian/human immunodeficiency virus (SHIV) 89.6P in macaques after coimmunization with SHIV antigen and IL-15 plasmid.Replicating and non-replicating viral vectors for vaccine developmentAntibodies to gp120 and PD-1 expression on virus-specific CD8+ T cells in protection from simian AIDSMucosal priming with a replicating-vaccinia virus-based vaccine elicits protective immunity to simian immunodeficiency virus challenge in rhesus monkeys.Macaques vaccinated with live-attenuated SIV control replication of heterologous virus.Sequential priming with simian immunodeficiency virus (SIV) DNA vaccines, with or without encoded cytokines, and a replicating adenovirus-SIV recombinant followed by protein boosting does not control a pathogenic SIVmac251 mucosal challengeComparative study of Tat vaccine regimens in Mauritian cynomolgus and Indian rhesus macaques: influence of Mauritian MHC haplotypes on susceptibility/resistance to SHIV(89.6P) infection.HIV-Tat immunization induces cross-clade neutralizing antibodies and CD4(+) T cell increases in antiretroviral-treated South African volunteers: a randomized phase II clinical trialA HIV-Tat/C4-binding protein chimera encoded by a DNA vaccine is highly immunogenic and contains acute EcoHIV infection in mice.Impact of antibody quality and anamnestic response on viremia control post-challenge in a combined Tat/Env vaccine regimen in rhesus macaques.Systemic neutralizing antibodies induced by long interval mucosally primed systemically boosted immunization correlate with protection from mucosal SHIV challenge.Contribution of nonneutralizing vaccine-elicited antibody activities to improved protective efficacy in rhesus macaques immunized with Tat/Env compared with multigenic vaccines.Live attenuated rubella vectors expressing SIV and HIV vaccine antigens replicate and elicit durable immune responses in rhesus macaques.The effects of HIV Tat DNA on regulating the immune response of HIV DNA vaccine in mice.Mucosal vaccination with a live recombinant rhinovirus followed by intradermal DNA administration elicits potent and protective HIV-specific immune responses.
P2860
Q22241377-7149A82C-C7D7-4A40-92FB-B81545CD5F47Q26861148-832F4E51-E084-4B2C-9476-2F6677752235Q30238730-AD3E1771-A19D-485B-96A3-A1B88A969937Q30375160-38FF95CE-73FA-4484-A249-530F527FFDB5Q30378897-AC3C08D8-8261-494C-BEDB-73CAE56BFF40Q30381447-2DDF5CA2-0556-47E5-8365-EAEDAD17E237Q33864926-72DADE4F-5F56-482D-9C0A-B024C68D4848Q33872445-88122749-F2E2-40D3-9288-76D79622B683Q33898131-F4574066-1572-453C-89E3-C3E6F47E491FQ33915690-E4FAC1D8-196A-44F4-8CAD-E7FB99B236BEQ33966586-804E0118-D270-4000-98FA-850400F0A7DBQ34016756-49D39F92-77D9-4B35-8F06-61C708630598Q34117097-03AA762A-B131-4B26-87FB-7D6602680239Q34148683-5ABDB8A7-7E2C-4CCA-86E9-76470FA9161AQ34477471-98B07F17-CFE6-478A-AECB-E10ED583C521Q34485178-9490050D-0FA2-4D35-9067-2F0D52D62770Q34616275-C8137343-0C52-47CE-9352-95907C32C2A7Q35021632-EBDE7BD3-97CB-47D5-A9B8-F1BAE64BCF37Q35032794-FB2DC064-0A2C-407B-A6DA-8C687900BF21Q35141486-81B389F8-274A-4E9A-9EE0-7AF6BB33F363Q35160124-58F71B1A-B092-48AB-9739-C8A159C46D7AQ35636394-1009EEF7-D58C-4DF0-B96D-69FD584A1FBEQ35867976-3D3CDAF7-15E1-4B3E-8F85-46851C68C165Q35883997-C16C3D01-6009-4985-9A4A-85C2A7FD1424Q36071414-EB824CC0-521C-47CA-ADF8-E6877C28E80AQ36276936-A693F3C5-C5B9-4754-8ED0-4B3FEE2B70D9Q36464587-7CFA384C-5239-4528-BC99-55773D945618Q36667821-3170E133-C7D0-4118-90B5-9E4EB26D336DQ36827361-307DC402-9404-4356-9DBF-1EA08EA0CE32Q36946545-58467D8B-083E-4029-B79D-1C84D63FCEEBQ36949703-4DC4CA5D-D07D-40D6-A846-2BAE567DA4B7Q36961218-96C0D931-FC36-4453-A425-9308E538BA0FQ36986644-34B59098-0502-47FC-B0A3-50B617A2DD6CQ37054470-06AD5DB7-4340-4CDA-BBF7-DF6779F991C5Q37096865-1AFB085B-0A2B-432F-BD1C-E51E7425C7DDQ37297052-FF6ACE37-1D13-481D-BE3A-F66204AA0DC8Q37347813-6DAB81EC-97F9-4745-8CA7-3D6DE567DE62Q37361294-4B88362F-0420-44A3-B139-24053D0C095EQ37364423-E5A055B8-4E98-4EA7-8AEF-B2C5FF6C0CBEQ37419985-5C869806-53A3-4A05-A00F-958D55A85ED7
P2860
A replication-competent adenovirus-human immunodeficiency virus (Ad-HIV) tat and Ad-HIV env priming/Tat and envelope protein boosting regimen elicits enhanced protective efficacy against simian/human immunodeficiency virus SHIV89.6P challenge in rhe
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
A replication-competent adenov ...... rus SHIV89.6P challenge in rhe
@ast
A replication-competent adenov ...... rus SHIV89.6P challenge in rhe
@en
type
label
A replication-competent adenov ...... rus SHIV89.6P challenge in rhe
@ast
A replication-competent adenov ...... rus SHIV89.6P challenge in rhe
@en
prefLabel
A replication-competent adenov ...... rus SHIV89.6P challenge in rhe
@ast
A replication-competent adenov ...... rus SHIV89.6P challenge in rhe
@en
P2093
P2860
P356
P1433
P1476
A replication-competent adenov ...... P challenge in rhesus macaques
@en
P2093
Adam Buzby
Aurelio Cafaro
David C Montefiori
David Venzon
Dilani Dombagoda
Eun Mi Lee
Irene Kalisz
Kay Larsen
L Jean Patterson
Marjorie Robert-Guroff
P2860
P304
P356
10.1128/JVI.02453-06
P407
P577
2007-01-17T00:00:00Z